The Journal of Practical Medicine ›› 2025, Vol. 41 ›› Issue (23): 3730-3736.doi: 10.3969/j.issn.1006-5725.2025.23.015

• Clinical Research • Previous Articles    

Relationship between serum F2IP, Hcy, cPLA2 and male erectile dysfunction

Debang LI1,Xiaojun ZHU2(),Pujia. REN3   

  1. *.Reproductive Center,Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,Inner Mongolia,China
  • Received:2025-08-08 Online:2025-12-10 Published:2025-12-18
  • Contact: Xiaojun ZHU E-mail:2728600785@qq.com

Abstract:

Objective To investigate the relationship between serum F2-isoprostaglandin (F2IP), homocysteine (Hcy), cytoplasmic phospholipase A2 (cPLA2) and male erectile dysfunction. Methods A total of 198 patients with erectile dysfunction who were admitted to the Affiliated Hospital of Inner Mongolia Medical University from January 2020 to April 2025 were selected as the case group. Meanwhile, 198 physical examinees with normal reproductive and sexual functions who underwent physical examinations in our hospital during the same period were selected as the control group. The levels of serum F2IP, Hcy, cPLA2, sex hormones, and the score of the international index of erectile function (IIEF) were measured and recorded in the two groups. Subsequently, the diagnostic value of serum F2IP, Hcy, and cPLA2 for male erectile dysfunction was analyzed. Based on the IIEF score, the patients with erectile dysfunction were classified into the severe group (45 cases), the moderate group (88 cases), and the mild group (65 cases). The levels of serum F2IP, Hcy, cPLA2, and sex hormones were compared among the three groups, and the correlation between the levels of serum F2IP, Hcy, cPLA2, sex hormones, and the IIEF score in patients with erectile dysfunction was analyzed. Results The levels of serum F2-isoprostane (F2IP), homocysteine (Hcy), cytosolic phospholipase A2 (cPLA2), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) in the case group were significantly higher than those in the control group, while the serum testosterone level and International Index of Erectile Function (IIEF) score were significantly lower than those in the control group (P < 0.05). The area under the curve (AUC) of the combined detection of serum F2IP, Hcy, and cPLA2 in the diagnosis of erectile dysfunction was higher than that of each biomarker alone (P < 0.05), with the sensitivity and specificity being 88.38% and 84.34%, respectively. In the mild, moderate, and severe groups, the levels of serum F2IP, Hcy, cPLA2, FSH, and LH exhibited an increasing trend, whereas the serum testosterone level showed a decreasing trend (P < 0.05). The levels of serum F2IP, Hcy, and cPLA2 in patients with erectile dysfunction were negatively correlated with the serum testosterone level and IIEF score (r = -0.573, -0.618, -0.549, -0.516, -0.553, -0.581; P < 0.05) and positively correlated with the levels of serum FSH and LH (r = 0.571, 0.650, 0.650, 0.511, 0.648, 0.547; P < 0.05). Conclusions The occurrence of erectile dysfunction can lead to an increase in the levels of serum F2IP, Hcy, and cPLA2, as well as an abnormality in the levels of serum sex hormones. Moreover, the combination of serum F2IP, Hcy, and cPLA2 can enhance the diagnostic value of erectile dysfunction. Meanwhile, there is a significant correlation between the levels of serum F2IP, Hcy, and cPLA2, the levels of serum sex hormones, and the severity of the disease.

Key words: erectile dysfunction, F2-isoprostaglandin, homocysteine, cytoplasmic phospholipase A2, sex hormones

CLC Number: